Arjan C Lankester
Overview
Explore the profile of Arjan C Lankester including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
164
Citations
3637
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Muskens K, Wieringa N, van Bergen M, Bense J, Te Pas B, de Pagter A, et al.
Blood Cancer Discov
. 2025 Jan;
6(2):110-118.
PMID: 39804695
As survival of HCT recipients continues to improve, late treatment effects gain importance. We demonstrate that pediatric HCT recipients show increased risk of CH compared with age-matched controls. Prospective studies...
2.
Gilioli G, Lankester A, de Kivit S, Staal F, Ott de Bruin L
Immunol Lett
. 2024 Sep;
270:106931.
PMID: 39303994
Mutations in the recombination activating genes (RAG) cause various forms of immune deficiency. Hematopoietic stem cell transplantation (HSCT) is the only cure for patients with severe manifestations of RAG deficiency;...
3.
Vissers L, van Ostaijen-Ten Dam M, Melsen J, van der Spek Y, Kemna K, Lankester A, et al.
Front Immunol
. 2024 Sep;
15:1328175.
PMID: 39229270
Introduction: Pediatric patients with unexplained bone marrow failure (BMF) are often categorized as aplastic anemia (AA). Based on the accepted hypothesis of an auto-immune mechanism underlying AA, immune suppressive therapy...
4.
Tsilifis C, Speckmann C, Lum S, Fox T, Soler A, Mozo Y, et al.
J Allergy Clin Immunol
. 2024 Sep;
154(6):1534-1544.
PMID: 39218359
Background: Cytotoxic T-lymphocyte antigen 4 (CTLA-4) insufficiency causes a primary immune regulatory disorder characterized by lymphoproliferation, dysgammaglobulinemia, and multiorgan autoimmunity including cytopenias and colitis. Objective: We examined the outcome of...
5.
Berghuis D, Mehyar L, Abu-Arja R, Albert M, Barnum J, von Bernuth H, et al.
J Clin Immunol
. 2024 Aug;
44(8):182.
PMID: 39167297
Immunodeficiency-Centromeric instability-Facial dysmorphism (ICF) syndrome is an inborn error of immunity characterized by progressive immune dysfunction and multi-organ disease usually treated with antimicrobial prophylaxis and immunoglobulin substitution. Allogeneic hematopoietic stem...
6.
Sorel N, Diaz-Pascual F, Bessot B, Sadek H, Mollet C, Chouteau M, et al.
Biomedicines
. 2024 Jul;
12(7).
PMID: 39062069
Recombinase-activating gene (RAG)-deficient SCID patients lack B and T lymphocytes due to the inability to rearrange immunoglobulin and T cell receptor genes. The two genes act as a required dimer...
7.
de Gier M, Pico-Knijnenburg I, van Ostaijen-Ten Dam M, Berghuis D, Smiers F, van Beek A, et al.
Front Immunol
. 2024 Jul;
15:1397567.
PMID: 39044816
Allogeneic hematopoietic stem cell transplantation (HSCT) is a curative treatment for various hematological, immunological and metabolic diseases, replacing the patient's hematopoietic system with donor-derived healthy hematopoietic stem cells. HSCT can...
8.
von Asmuth E, Hiensch F, Heidt S, Mohseny A, Roelen D, Kramer C, et al.
Blood Adv
. 2024 Jul;
8(18):4767-4777.
PMID: 38985189
Allogeneic hematopoietic stem cell transplantation (HSCT) with mismatched unrelated donors (MMUD) is associated with inferior outcome compared with matched unrelated donors (MUDs). We aimed to identify permissible mismatches using HLA...
9.
Oostenbrink L, von Asmuth E, Jol-van der Zijde C, Jansen-Hoogendijk A, Vervat C, Bredius R, et al.
Haematologica
. 2024 May;
109(9):2854-2863.
PMID: 38721739
Anti-T-lymphocyte globulin (ATLG) is used in hematopoietic stem cell transplantation (HSCT) to prevent graft-versus-host disease (GVHD) and graft failure. To date, insight in ATLG pharmacokinetics and -dynamics (PK/PD) is limited,...
10.
Bense J, Guilonard N, Zwaginga F, Stiggelbout A, Louwerens M, Mekelenkamp H, et al.
Health Expect
. 2023 Dec;
27(1):e13902.
PMID: 38102818
Introduction: The assessment of using patient-reported outcomes (PROs) within comprehensive care follow-up programmes, specifically focused on health screening, remains largely unexplored. PROs were implemented in our late effects and comprehensive...